Dazucorilant - Corcept Therapeutics
Alternative Names: CORT-113176Latest Information Update: 19 Jul 2024
At a glance
- Originator Corcept Therapeutics
- Class Anti-inflammatories; Fluorobenzenes; Isoquinolines; Ketones; Lipids; Neuroprotectants; Pyrazoles; Pyridines; Small molecules; Sulfones
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
Most Recent Events
- 31 May 2024 Corcept Therapeutics initiates a phase I drug drug interaction trial in healthy adult volunteers in USA (PO, Capsule) (NCT06495944)
- 15 Apr 2024 Corcept Therapeutics completes enrollment in the phase II DAZALS trial in Amyotrophic lateral sclerosis in Belgium, France, Canada, Ireland, United Kingdom, Germany, Poland, Spain, Netherlands and USA (PO) (NCT05407324) (EudraCT2021-005611-31)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In volunteers) in United Kingdom (PO, Capsule)